Table 4.
Association between aPS/PT IgG antibody positivity rate and clinical manifestations.
| Clinical parameter | Total of 103 patients n (%) | At least one positive determination vs. double negatives | Both determinations with positive results vs. negative or single positive | ||||||
|---|---|---|---|---|---|---|---|---|---|
| aPS/PT IgG Pos (n = 15) | aPS/PT IgG Neg (n = 88) | p value | Odds ratio (95% CI) | aPS/PT IgG Pos (n = 9) | aPS/PT IgG Neg (n = 94) | p value | Odds ratio (95% CI) | ||
| APS | 25 (24) | 8 (53) | 17 (19) | <0.01 | 4.7 (1.3–17.6) | 7 (78) | 18 (19) | <0.01 | 14.3 (2.5–151.8) |
| Thrombosis | 34 (33) | 9 (60) | 25 (28) | <0.05 | 3.7 (1.1–14.2) | 7 (78) | 27 (29) | <0.01 | 8.5 (1.5–88.8) |
| Pregnancy morbidity a | 16/28 (56.1) | 1 (20) | 15 (65) | 0.1331 | 0.144 (0.0003–1.770) | 1 (33) | 15 (60) | 0.5604 | 0.347 (0.005–7.503) |
| SLE | 38 (37) | 9 (60) | 29 (33) | 0.08 | 3.0 (0.9–11.4) | 2 (22) | 32 (34) | 0.07 | 3.8 (0.8–25.2) |
| Triple Positive | 20 (19) | 7 (47) | 13 (15) | <0.01 | 5.0 (1.3–18.9) | 7 (78) | 13 (14) | <0.01 | 20.8 (3.5–225.8) |
| LA | 27/101 (27) | 8 (53) | 19/86 (22) | <0.05 | 4.0 (1.1–14.7) | 8 (89) | 19/86 (22) | <0.01 | 29.5 (3.6–1381.6) |
| GAPSS > 9 | 32/85 (38) | 10/14 (71) | 22/71 (31) | <0.01 | 5.4 (1.4–26.5) | 8/9 (89) | 24/76 (32) | <0.01 | 16.8 (2.1–783.4) |
Values of categorical variables are expressed as number and (percentage).
aData calculated on the total number of women who have had at least one pregnancy (n = 28).
APS, anti-phospholipid syndrome; SLE, systemic lupus erythematous; LA, lupus anticoagulant; GAPSS, Global Antiphospholipid Syndrome Score; Pos, positive; Neg, negative; aPS/PT, anti-phosphatidylserine/prothrombin antibodies.
Bold means statistically significant values.